Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistant Stenotrophomonas maltophilia
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2828 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Ashlan J Kunz Coyne und 3 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Anti-Infective Agents, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 108 Literaturangaben.
Abstract (Originalsprache)
Stenotrophomonas maltophilia is an opportunistic pathogen and frequent cause of serious nosocomial infections. Patient populations at greatest risk for these infections include the immunocompromised and those with chronic respiratory illnesses and prior antibiotic exposure, notably to carbapenems. Its complex virulence and resistance profile drastically limit available antibiotics, and incomplete breakpoint and pharmacokinetic/pharmacodynamic (PK/PD) data to inform dose optimization further complicates therapeutic approaches. Clinical comparison data of first‐line agents, including trimethoprim‐sulfamethoxazole (TMP‐SMX), quinolones, and minocycline, are limited to conflicting observational data with no clear benefit of a single agent or combination therapy. Newer antibiotic approaches, including cefiderocol and aztreonam‐ avibactam, are promising alternatives for extensively drug‐resistant isolates; however, clinical outcomes data are needed. The potential clinical utility of bacteriophage for compassionate use in treating S. maltophilia infections remains to be determined since data is limited to in‐vitro and sparse in‐vivo work. This article provides a review of available literature for S. maltophilia infection management focused on related epidemiology, resistance mechanisms, identification, susceptibility testing, antimicrobial PK/PD, and emerging therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- Henry Ford Wyandotte, Wyandotte, Michigan, USA.
- School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Pharmacy Services, Detroit Receiving Hospital, Detroit, Michigan, USA.
ORCID-Profile: Ashlan J Kunz Coyne, Shelbye Herbin, Kaylee Caniff, Michael J Rybak
Zitieren
APA
Kunz Coyne, A. J., Herbin, S., Caniff, K., & Rybak, M. J. (2023). Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistant Stenotrophomonas maltophilia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2828
Vancouver
Kunz Coyne AJ, Herbin S, Caniff K, Rybak MJ. Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistant Stenotrophomonas maltophilia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2828
BibTeX
@article{KunzCoyne2023,
author = {Kunz Coyne, Ashlan J and Herbin, Shelbye and Caniff, Kaylee and Rybak, Michael J},
title = {Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistant Stenotrophomonas maltophilia},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2828}
}
EUVIMED